R&D channel feed

Boehringer In­gel­heim plans PhI­II chron­ic kid­ney dis­ease tri­al for al­dos­terone-tar­get­ing drug af­ter mid-stage suc­cess

Last year

Kro­nos Bio ax­es near­ly one-fifth of staff to pre­serve cash for two can­cer pro­grams

Last year
People

In­tel­lia sug­gests AT­TR amy­loi­do­sis gene edit­ing treat­ment has over a year of dura­bil­i­ty as it gears up for PhI­II

Last year
Cell/Gene Tx

Seres Ther­a­peu­tics sheds about 160 jobs to fo­cus on com­mer­cial C. diff pill

Last year
People

Mede­or’s cell ther­a­py boosts im­mune tol­er­ance in reg­is­tra­tional tri­al of donor kid­ney re­cip­i­ents

Last year
Cell/Gene Tx

Up­dat­ed: Eli Lil­ly's Moun­jaro sales hit $1.4B for the quar­ter, but FDA de­ci­sion on Alzheimer's drug is de­layed

Last year

Ro­bot­ic pill mak­er Rani paus­es pro­grams, cuts head­count to ex­tend cash run­way through 2025

Last year
People

Sang­amo lays off 160+ staffers, winds down fa­cil­i­ty, punts clin­i­cal pro­grams in dras­tic re­vamp

Last year
People

Si­lence un­veils more PhI da­ta for siR­NA drug in new car­dio­vas­cu­lar race tar­get­ing Lp(a)

Last year

Af­ter the ap­plause: New ef­fi­ca­cy ex­pec­ta­tions in urothe­lial can­cer af­ter Pad­cev-Keytru­da da­ta re­veal

Last year
Pharma
In Focus

GSK touts Arexvy sales as it dom­i­nates US old­er adult RSV mar­ket, com­pa­ny cuts three ear­ly-stage as­sets

Last year
Pharma

Ver­tex doesn’t need to do more test­ing for rogue gene ed­its from sick­le cell ther­a­py tri­al, FDA ad­vi­sors say

Last year
FDA+

Long­time can­cer R&D chief Pe­ter Lebowitz is tak­ing his fi­nal bows at J&J on­col­o­gy. Now what?

Last year
Bioregnum

FDA lifts clin­i­cal hold on Mer­sana’s STING ag­o­nist, PhI start­ing dose low­ered af­ter pa­tient death

Last year

As Sarep­ta ex­ecs talk up Duchenne con­fir­ma­to­ry tri­al re­sults, in­vestors and an­a­lysts re­main di­vid­ed on how flex­i­ble FDA will be

Last year
FDA+

GSK steps in for J&J’s li­cense of Ar­row­head’s he­pati­tis B drug, plans com­bo study with its own can­di­date

Last year
Deals
Pharma

En­gine Bio­sciences bags $27M Se­ries A ex­ten­sion to ad­vance pre­ci­sion med­i­cine plat­form in on­col­o­gy

Last year
Financing

Sarep­ta's con­fir­ma­to­ry Duchenne tri­al fails to meet end­point, com­pli­cat­ing fu­ture for con­tro­ver­sial drug

Last year
Cell/Gene Tx

De­ci­phera says its drug for rare joint tu­mor suc­ceed­ed in a PhI­II study, will sub­mit to FDA

Last year

Post-pan­dem­ic and flush with cash, Vir eyes new fron­tiers in on­col­o­gy and neu­rol­o­gy

Last year

Mer­ck KGaA pays $169M up­front in deal for Hen­grui’s PARP1 in­hibitor and ADC

Last year
Deals

No­var­tis plans for po­ten­tial ac­cel­er­at­ed ap­proval for kid­ney dis­ease drug af­ter PhI­II in­ter­im analy­sis re­sult

Last year

GSK's Jem­per­li meets over­all sur­vival pri­ma­ry end­point in PhI­II study

Last year

Re­gen­eron gives first glimpse at hear­ing loss gene ther­a­py

Last year
Cell/Gene Tx
First page Previous page 65666768697071 Next page Last page
A service from the Financial Times